Suzanne M Cadarette
Overview
Explore the profile of Suzanne M Cadarette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tilli T, Mathers A, Lin Q, Bhaidani S, Baker J, Wei L, et al.
Can Pharm J (Ott)
. 2024 May;
157(3):143-152.
PMID: 38737357
Background: Community pharmacies typically require patients to request medication refills. The appointment-based model (ABM) is a proactive approach that synchronizes refills and schedules patient-pharmacist appointments. These appointments provide opportunities for...
2.
Rzepka A, Cheung A, Kim S, Gomes T, Cadarette S
JBMR Plus
. 2024 Apr;
8(5):ziae027.
PMID: 38623483
Timely administration of denosumab every 6 mo is critical in osteoporosis treatment to avoid multiple vertebral fracture risk upon denosumab discontinuation or delay. This study aimed to estimate the immediate...
3.
Hayes K, Cadarette S, Burden A
Bone Rep
. 2023 Dec;
20:101730.
PMID: 38145014
Observational studies of osteoporosis medications can provide critical real-world evidence (RWE) that fills knowledge gaps left by clinical trials. However, careful consideration of study design is needed to yield reliable...
4.
Morin S, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al.
CMAJ
. 2023 Nov;
195(46):E1585-E1603.
PMID: 38011931
No abstract available.
5.
Morin S, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al.
CMAJ
. 2023 Oct;
195(39):E1333-E1348.
PMID: 37816527
Background: In Canada, more than 2 million people live with osteoporosis, a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life...
6.
Lin Q, Mathers A, Tilli T, Baker J, Bhaidani S, Grootendorst P, et al.
Res Social Adm Pharm
. 2023 Jun;
19(9):1286-1291.
PMID: 37286385
Background: Traditionally, much of community pharmacy practice relies on patients to request their own medication refills. These refills are often not aligned, which has been shown to decrease adherence and...
7.
Konstantelos N, Burden A, Cheung A, Kim S, Grootendorst P, Cadarette S
Pharmacy (Basel)
. 2023 Mar;
11(2).
PMID: 36961031
We identified inconsistency in fracture definitions in a prior review of studies that utilized claims data. Here, we aimed to compare fracture rates estimated using thirteen hip and seven radius/ulna...
8.
Rzepka A, Wong L, Chaudhry M, Sproule B, He N, Cadarette S
Can Pharm J (Ott)
. 2022 Jul;
155(4):194-199.
PMID: 35813528
No abstract available.
9.
Gan Q, Loi A, Chaudhry M, He N, Shakeri A, Dolovich L, et al.
Can Pharm J (Ott)
. 2022 May;
155(3):151-156.
PMID: 35519084
No abstract available.
10.
Hayes K, Brown K, Cheung A, Kim S, Juurlink D, Cadarette S
Ann Intern Med
. 2022 Jan;
175(3):335-343.
PMID: 35007149
Background: An osteoporosis drug holiday is recommended for most patients after 3 to 5 years of therapy. Risedronate has a shorter half-life than alendronate, and thus the residual length of...